These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells. Mankhetkorn S, Dubru F, Hesschenbrouck J, Fiallo M, Garnier-Suillerot A. Mol Pharmacol; 1996 Mar; 49(3):532-9. PubMed ID: 8643093 [Abstract] [Full Text] [Related]
4. Can cytotoxic activity of anthracyclines be related to DNA damage? Nishiyama M, Horichi N, Mazouzi Z, Bungo M, Saijo N, Tapiero H. Anticancer Drug Des; 1990 Feb; 5(1):135-9. PubMed ID: 2317255 [Abstract] [Full Text] [Related]
5. Cellular pharmacology of MX2, a new morpholino anthracycline, in human pleiotropic drug-resistant cells. Watanabe M, Komeshima N, Naito M, Isoe T, Otake N, Tsuruo T. Cancer Res; 1991 Jan 01; 51(1):157-61. PubMed ID: 1988080 [Abstract] [Full Text] [Related]
6. Localization of anthracycline accumulation in sensitive and resistant urothelial tumor cell lines. Davies CL, Duffy PM, MacRobert AJ, Loizidou MC, Cooper AJ, Taylor I. Cancer Detect Prev; 1996 Jan 01; 20(6):625-33. PubMed ID: 8939349 [Abstract] [Full Text] [Related]
7. [Intracellular measurement of anthracyclines with flow cytometry]. Dorn A, Graf N, Pees HW. Padiatr Padol; 1993 Jan 01; 28(6):157-63. PubMed ID: 8302622 [Abstract] [Full Text] [Related]
8. [Pharmacokinetics of new anthracyclines]. Robert J. Bull Cancer; 1988 Jan 01; 75(2):167-74. PubMed ID: 3282579 [Abstract] [Full Text] [Related]
9. The ability of verapamil to restore intracellular accumulation of anthracyclines in multidrug resistant cells depends on the kinetics of their uptake. Mankhetkorn S, Garnier-Suillerot A. Eur J Pharmacol; 1998 Feb 19; 343(2-3):313-21. PubMed ID: 9570481 [Abstract] [Full Text] [Related]
15. Cross resistance relevance of the chemical structure of different anthracyclines in multidrug resistant cells. Tapiero H, Nguyen-Ba G, Lampidis TJ. Pathol Biol (Paris); 1994 Apr 19; 42(4):328-37. PubMed ID: 7808786 [Abstract] [Full Text] [Related]
16. Comparison of idarubicin and daunorubicin and their main metabolites regarding intracellular uptake and effect on sensitive and multidrug-resistant HL60 cells. Tidefelt U, Prenkert M, Paul C. Cancer Chemother Pharmacol; 1996 Apr 19; 38(5):476-80. PubMed ID: 8765443 [Abstract] [Full Text] [Related]
17. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA. Bodley A, Liu LF, Israel M, Seshadri R, Koseki Y, Giuliani FC, Kirschenbaum S, Silber R, Potmesil M. Cancer Res; 1989 Nov 01; 49(21):5969-78. PubMed ID: 2551497 [Abstract] [Full Text] [Related]
18. WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity. Faderl S, Estrov Z, Kantarjian HM, Harris D, Van Q, Fokt I, Przewloka T, Godlewski C, Woynarowski JM, Priebe W. Anticancer Res; 2001 Nov 01; 21(6A):3777-84. PubMed ID: 11911247 [Abstract] [Full Text] [Related]
19. Reversal of doxorubicin resistance in multidrug resistant melanoma cells in vitro and in vivo by dipyridamole. Desai PB, Duan J, Sridhar R, Damle BD. Methods Find Exp Clin Pharmacol; 1997 May 01; 19(4):231-9. PubMed ID: 9228648 [Abstract] [Full Text] [Related]